ABT - Abbott Laboratories Profile, Share Price, Market Analysis, Charts, Fundamentals

Business Description

Company Profile: Abbott Laboratories

Overview:
Abbott Laboratories is a global healthcare company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare products. The firm is dedicated to improving the health of people worldwide through innovative products in pharmaceuticals, diagnostics, nutrition, and medical devices.

Headquarters:
Abbott Park, Illinois, USA

Reportable Segments:
Abbott operates through four key segments:
1. Pharmaceutical Products: Encompasses prescription medications and treatments across various therapeutic areas.
2. Diagnostic Products: Focuses on in vitro diagnostics and testing for various diseases and conditions.
3. Nutrition Products: Markets nutritional products for infants, children, and adults, including brands like Similac, PediaSure, and Ensure.
4. International: Represents geographical markets outside the United States, integrating both pharmaceutical and nutritional products as well as hospital products.

Additionally, Abbott holds a 50% interest in TAP Pharmaceutical Products Inc. a joint venture that enhances its pharmaceutical marketing efforts.

History and Development:
In August 2003, Abbott made a strategic decision to separate its core hospital products business into a new publicly traded company, Hospira, Inc. This move aimed to streamline operations and focus on core competencies, allowing Abbott to retain its pharmaceutical, diagnostic, and nutritional businesses while transitioning its hospital product aspect to Hospira, which includes medication delivery systems, critical care devices, and specialty injectable pharmaceuticals.

Distribution Channels:
- Pharmaceutical Products: These are marketed directly to wholesalers, healthcare facilities, and government agencies from Abbott-owned distribution centers.
- Diagnostic Products: Distributed through direct sales to hospitals, laboratories, and clinics, with significant products sold globally, including blood glucose monitoring systems.
- Nutrition Products: Primarily sold to retailers, wholesalers, and healthcare facilities, with direct marketing efforts focused on achieving healthcare professional endorsements.
- International Products: Distributed through a blend of direct sales and partnerships with local distributors for global reach in pharmaceuticals and nutritional products.

Competition:
Abbott operates in a highly competitive environment characterized by:
- Pharmaceutical Products: Competing with other healthcare and pharmaceutical companies, facing pressures from technological innovations, product obsolescence, and price competition, particularly due to generic substitutions.
- Diagnostic Products: Competing on innovation, price, and service, with products subject to rapid obsolescence.
- Hospital Products: Competition focused on technological advances, long-term supply contracts, and product performance, leading to potential obsolescence.
- Nutrition Products: Competing with diverse consumer health companies whose strategies involve advertising, formulation, packaging, and price.

Notable Products:
- Pharmaceuticals: Prescription medications targeting various health conditions, leveraging innovative therapies.
- Diagnostics: Advanced diagnostic tools and tests for disease management and monitoring.
- Nutritionals: Products such as Ensure, Glucerna, and PediaSure, developed for specific dietary needs across different age groups.

Commitment to Innovation:
Abbott emphasizes continuous innovation across all product segments to address evolving healthcare challenges and consumer needs, investing in research and development to launch new and improved healthcare solutions globally.

Abbotts robust portfolio and strategic initiatives continue to position it as a leader in the healthcare market, with a commitment to enhancing health outcomes for people worldwide.

Abbott Faces Trial Over Claims That Preterm Infant Formula Caused Dangerous Disease Ensuring Safety in Neonatal Care

Published Wed, Jul 10 2024 8:16 PM UTC

Abbott Laboratories, the maker of Similac baby formula, is set to face a trial on Monday regarding allegations that its preterm infant formula used in neonatal intensive care units (NICUs) has led to the development of a potentially life-threatening bowel disease. This article examines the case and delves into the importance of ensuring the safety and efficacy of infant form...

Fundamental Analysis

United States

38.28 %

of total Revenue

International

61.72 %

of total Revenue

Established Pharmaceuticals

12.77 %

of total Revenue

Established Pharmaceuticals Key Emerging Markets

9.75 %

of total Revenue

Established Pharmaceuticals Other

3.02 %

of total Revenue

Nutritional Products

18.07 %

of total Revenue

Nutritional Products Pediatric Nutritionals

8.54 %

of total Revenue

Nutritional Products Adult Nutritionals

9.53 %

of total Revenue

Diagnostic Products

19.53 %

of total Revenue

Diagnostic Products Core Laboratory

11.39 %

of total Revenue

Diagnostic Products Rapid and Molecular

7.27 %

of total Revenue

Diagnostic Products Cancer Diagnostics

0.86 %

of total Revenue

Medical Devices

49.61 %

of total Revenue

Medical Devices Rhythm Management

6.13 %

of total Revenue

Medical Devices Electrophysiology

7.06 %

of total Revenue

Medical Devices Heart Failure

3.48 %

of total Revenue

Medical Devices Vascular

6.96 %

of total Revenue

Medical Devices Structural Heart

5.18 %

of total Revenue

Medical Devices Neuromodulation

2.18 %

of total Revenue

Medical Devices Diabetes Care

18.63 %

of total Revenue

United States Nutritional Products

7.56 %

of total Revenue

United States Nutritional Products Pediatric Nutritionals

4.58 %

of total Revenue

United States Nutritional Products Adult Nutritionals

2.98 %

of total Revenue

United States Diagnostic Products

8.11 %

of total Revenue

United States Diagnostic Products Core Laboratory

3.11 %

of total Revenue

United States Diagnostic Products Rapid and Molecular

4.17 %

of total Revenue

United States Diagnostic Products Cancer Diagnostics

0.83 %

of total Revenue

United States Medical Devices

22.6 %

of total Revenue

United States Medical Devices Rhythm Management

3.04 %

of total Revenue

United States Medical Devices Electrophysiology

3.39 %

of total Revenue

United States Medical Devices Heart Failure

2.62 %

of total Revenue

United States Medical Devices Vascular

2.61 %

of total Revenue

United States Medical Devices Structural Heart

2.01 %

of total Revenue

United States Medical Devices Neuromodulation

1.59 %

of total Revenue

United States Medical Devices Diabetes Care

7.36 %

of total Revenue

International Established Pharmaceuticals

12.77 %

of total Revenue

International Established Pharmaceuticals Key Emerging Markets

9.75 %

of total Revenue

International Established Pharmaceuticals Other

3.02 %

of total Revenue

International Nutritional Products

10.51 %

of total Revenue

International Nutritional Products Pediatric Nutritionals

3.96 %

of total Revenue

International Nutritional Products Adult Nutritionals

6.55 %

of total Revenue

International Diagnostic Products

11.42 %

of total Revenue

International Diagnostic Products Core Laboratory

8.29 %

of total Revenue

International Diagnostic Products Rapid and Molecular

3.11 %

of total Revenue

International Diagnostic Products Cancer Diagnostics

0.03 %

of total Revenue

International Medical Devices

27.02 %

of total Revenue

International Medical Devices Rhythm Management

3.09 %

of total Revenue

International Medical Devices Electrophysiology

3.67 %

of total Revenue

International Medical Devices Heart Failure

0.87 %

of total Revenue

International Medical Devices Vascular

4.35 %

of total Revenue

International Medical Devices Structural Heart

3.17 %

of total Revenue

International Medical Devices Neuromodulation

0.59 %

of total Revenue

International Medical Devices Diabetes Care

11.27 %

of total Revenue

Other

0.02 %

of total Revenue

Other United States

0.02 %

of total Revenue

Abbott Laboratories Company Profile

Business Description

Abbott Faces Trial Over Claims That Preterm Infant Formula Caused Dangerous Disease Ensuring Safety in Neonatal Care

Fundamental Analysis